Objectives: To assess clinicopathological data and oncological outcomes focused on metastatic testicular cancer patients, who received chemotherapy as the initial treatment, in the nationwide multi-institutional study by the Cancer Registration Committee of the Japanese Urological Association. Methods: A testicular cancer survey was carried out by the Japanese Urological Association in 2011 to register newly diagnosed testicular cancers in 2005 and 2008. Among 1121 registered patients, 278 patients with metastases who received chemotherapy as the initial treatment and could be categorized by the Japanese Urological Association classification were eligible for the analysis. Results: As first-line chemotherapy, bleomycin, etoposide and cisplatin, and etoposide and cisplatin therapies were chosen for 260 patients (93.5%). As second-line therapy, vinblastine, ifosfamide and cisplatin/etoposide, ifosfamide and cisplatin; and paclitaxel, ifosfamide and cisplatin/paclitaxel, ifosfamide and nedaplatin therapies were carried out in 23 out of 63 (36.5%) and 29 out of 63 (46.0%) patients, respectively. The response rate and serum tumor marker normalization rate were 93.4% and 81.3% at first line, 75.4% and 60.7% at second line, and 41.7% and 16.7% at third line, respectively. The Japanese Urological Association classification (≥IIIB2 vs ≤IIIB1) and choriocarcinoma component in primary histology were independent prognostic factors of overall survival before starting chemotherapy. Furthermore, in patients with non-seminomatous germ cell tumors, serum tumor marker normalization was an independent factor that was associated with better outcome of overall survival after completion of the initial series of chemotherapies. Conclusions: The initial accurate diagnosis and risk stratification is an important prognostic factor to achieve better oncological outcomes. In patients with nonseminomatous germ cell tumors, aiming for serum tumor marker normalization with continuous sequential chemotherapy could improve overall survival.
Introduction
Cisplatin-based chemotherapy has greatly improved the survival of patients with GCTs. 1, 2 Even in advanced metastatic GCTs, approximately 80% of patients can be cured. [3] [4] [5] Thus, there is no doubt that chemotherapy plays a central role in managing metastatic testicular cancer patients.
Recently, the first large-scale study of the characteristics and survival of testicular cancer patients in Japan based on multi-institutional registry has been reported. 6 The report showed that improved survival was substantially attributed to accurate diagnosis and effective multimodal treatment. Furthermore, Kawai et al. reported the characteristics of testicular GCTs in patients aged ≥50 years from the same database. 7 It is important to investigate the clinicopathological data and oncological outcomes that track the trend and response of chemotherapeutic treatment in patients with metastatic testicular GCT in Japan. The objective of the present study was to clarify the trend of chemotherapeutic treatment and the factors related to clinical outcomes in patients with metastatic testicular GCTs in Japan.
Methods
The Cancer Registration Committee of the JUA carried out a testicular cancer registry program in 2011 to collect the data of patients with testicular cancer diagnosed in 2005 and 2008 from the accredited training institutes for board certification in urology. The survey included details such as age, presenting symptoms, physical examination findings, tumor markers, histopathology, clinical stage, initial treatment and clinical outcomes. Evaluation of symptoms, tumor markers, clinical stage, initial treatment and survival data from the entire cohort has been previously reported. 6 Among 1121 registered patients with testicular primary GCT, 344 patients were diagnosed as metastatic testicular cancer that can be classified by the JUA staging system (Appendix I). Excluding 14 patients whose treatment was not documented, 330 patients were analyzed in the study. Among them, 278 patients underwent chemotherapy as the initial treatment (Fig. 1, Table S1 ). We clarified the trend of chemotherapeutic treatment and factors related to clinical outcomes in the 278 patients.
CR was defined as the disappearance of all clinically detectable disease and as STM normalization. PR was defined as >30% reduction of the tumor size. STM normalization was defined as normal STM regardless of tumor shrinkage. RR was defined as CR + PR regardless of STM normalization. The status of RR and STM normalization was not documented in 19 and 59 patients, respectively.
Statistical differences for intergroup comparison were analyzed by Fisher's exact probability test and the v 2 -test as appropriate. Survival rates were calculated using the KaplanMeier method and compared by the log-rank test. The Cox proportional hazards model was applied to examine factors that are associated with survival. P < 0.05 was designated as statistical significance. All statistical analyses were carried out with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R foundation for Statistical Computing, Vienna, Austria). More precisely, it is a modified version of R commander designed to add statistical functions frequently used in biostatistics. 8 
Results

Treatment for metastatic testicular GCTs
Among 330 cases, 278 (84.2%) patients received chemotherapy as the initial treatment (Fig. 1) . Radiation therapy was carried out in 19 patients (5.8%), in which 18 patients had seminoma and 17 patients had stage IIA disease (Fig. 1 , Table S1 ). The surveillance option was selected in 26 patients (7.9%), where 22 patients were categorized in stage III0. According to the the IGCCC risk criteria, 88 (75.2%) good-, 75 (96.2%) intermediate-and 52 (96.3%) poor-risk patients received chemotherapy. However, the IGCCC risk criteria were not applied to 81 patients because of invalid measurement of HCG, as described in a previous report. 6 A total of 23 patients (8.3%) died from the disease during the observation period of 0-72 months, with a median of 31 months.
Patients' characteristics and chemotherapy sequence
Of 278 patients, 227 (81.7%) patients received only one chemotherapy regimen and 51 (18.3%) patients required two or more regimens to complete initial chemotherapy aiming for STM normalization (Table 1) . Patients who required two or more regimens had worse JUA stage and IGCCC risk criteria compared with those who received only one chemotherapy regimen. Table 2 lists the treatment sequence with other additional procedures. The combination chemotherapy of the BEP/EP regimen was chosen for 260 patients (93.5%) as induction therapy. Regarding second-line therapy including patients who recurred after first-line chemotherapy, VeIP/VIP and TIP/TIN therapies were carried out for 23 (36.5%) and 29 (46.0%) patients, respectively. As third-line therapy, five (38.5%) patients received TIP/ TIN therapy, and IrP/IrN regimen was selected for three (23.1%) patients. In terms of additional procedures, residual mass resections and radiation therapies after first-line chemotherapy were carried out for 65 (23.4%) and six (2.2%) patients, respectively. RR and STM normalization rate at each chemotherapy line stratified by regimen
The RRs (CR and PR) and STM normalization rates for the first-, second-, third-and fourth-line or greater chemotherapies are described in Table 3 . In total, RRs and STM normalization rates were 93.3% and 81.3% at first line, 74.1% and 58.5% at second line, 41.7% and 16.7% at third line, and 41.7% and 16.7% at fourth line or greater, respectively. As induction therapy, BEP/EP regimens showed 98.6% of RR and 92.7% of STM normalization rate in seminoma patients, and 91.2% of RR and 77.4% of STM normalization rate in patients with NSGCT. In second-line therapy, STM normalization rates in response to VeIP/VIP and TIP/TIN were 45.0% and 58.3%, respectively. Statistical differences were not observed between VeIP/VIP and TIP/TIN in terms of RR, STM normalization rate and 3-year OSs with similar patient characteristics (Table 3, Tables S2,S3 , Fig. S1 ). TIP/TIN regimens showed 50.0% STM normalization rate in third-line therapy.
Factors related to OS before starting chemotherapy
As shown in Figure 2 , IGCCC risk criteria, JUA classification, NSGCT classification and the presence of a choriocarcinoma component in primary histology were significantly First-line chemotherapy only indicates the patients who received only one chemotherapy regimen. Second-line or greater chemotherapy indicates the patients who required two or more regimens to complete the initial series of chemotherapy. The NSGCT classification includes pure seminoma with AFP >20 ng/mL. JUA classification: See Appendix I. associated with OS before starting chemotherapy. Other factors including age and histological component including seminoma, embryonal carcinoma, teratoma and york sac tumor were not statistically significant (data not shown). Cox regression analysis was carried out using variables including JUA classification, NSGCT classification and the presence of choriocarcinoma histology at the time of diagnosis that showed significant difference by the log-rank test. In this analysis, the variable of IGCCC risk criteria was excluded, because the IGCCC risk criteria were not determined in 63 (22.7%) patients, which might affect the analysis. The cut-off point of the JUA classification (≥IIIB2 vs ≤IIIB1) was chosen because the largest significant difference was observed. The JUA classification (≥IIIB2 vs ≤IIIB1) and histopathological finding of a choriocarcinoma component in primary histology were independent prognostic factors of OS before starting chemotherapy (Table 4) .
Factors related to OS after completion of the initial series of chemotherapy in patients with NSGCT
To investigate factors related to OS after completion of the initial series of chemotherapy, we focused on patients with NSGCT, because seminoma patients in this cohort had a good prognosis and just two (2.6%) of 76 patients died during observation periods. As shown in Figure 3 , IGCCC risk criteria, JUA classification (≥IIIB2 vs ≤IIIB1), the presence of a choriocarcinoma component in primary histology, required number of chemotherapy lines, RR (CR + PR) and STM normalization were significantly associated with OS. Other factors including age and histological component (seminoma, embryonal carcinoma, teratoma and york sac tumor) were not statistically significant (data not shown). Multivariate analysis was carried out using variables that that were shown to be statistically significant by the log-rank test, as shown in Figure 3 . Achieving STM normalization was an independent prognostic factor that was associated with OS after completion of the initial series of chemotherapy in patients with NSGCT (Table 4) . 
Discussion
The present study was a subanalysis of a nationwide multiinstitutional study of testicular GCTs carried out by the Cancer Registration Committee of the Japanese Urological Association. We focused on metastatic GCT patients who received chemotherapy as the initial treatment to evaluate the trend and oncological outcomes of chemotherapy for metastatic GCTs in Japan based on multi-institutional registry data. The results showed that initial accurate diagnosis and staging are important to manage metastatic GCT patients, and continuous sequential chemotherapies aiming for STM normalization with multimodal treatment is the key strategy to improve OS in patients with metastatic GCT. Approximately 80% of patients with advanced, metastatic GCTs could achieve a continuous CR to initial treatment with cisplatin and etoposide with or without bleomycin (BEP/EP). 9 In the present study, BEP/EP therapy was applied to 93.5% of patients with metastatic GCTs, and showed good outcomes with 93.3% RR and 81.3% STM normalization rate. In contrast, the VeIP/VIP regimen as first-line chemotherapy was used in 5.0% of patients, resulting in a STM normalization rate of 45.5%. The reason for the reduced effectiveness of VeIP/ VIP compared with BEP/EP might be that VeIP/VIP was used in patients with a more advanced stage in the present study; in fact, 57.1% (8/14) and 28.6% (4/14) of patients who received VeIP/VIP as first-line chemotherapy were stage IIIB2 and IIIC in the JUA classification.
Although VeIP/VIP therapy has been used as second-line therapy, the rate of long-term remission was approximately 30%. 10, 11 On account of these unsatisfactory results, other combination chemotherapies have been tested and TIP therapy has been recognized as a standard first salvage chemotherapy. 12, 13 In the current Japanese registry study, the most common choice for second-line chemotherapy was TIP/ TIN regimen where the RR and STM normalization rate were 74.1% and 58.3%, respectively. The results seem consistent with or even superior to a previous report. 13 Meanwhile, statistical differences were not observed between VeIP/VIP and TIP/TIN in terms of RR, STM normalization rate and 3-year OSs with similar patient characteristics, such as IGCCC classification and JUA classification (Tables S1,S2, Fig. S1 ). These results indicate the possibility that the VeIP/VIP regimen is still a good candidate for salvage chemotherapy, at least as a second-line setting for patients with BEP/EP failure. However, long-term follow up or comparative analysis should be required to conclude the results.
As researchers realized that certain clinical and tumor characteristics could predict the likelihood of patient response to chemotherapy regimens, the IGCCC risk criteria were developed as a universal classification scheme. 3 In this stratification system, patients are separated into good-, intermediate-and poor-prognosis groups according to the predicted outcome to cisplatin combination chemotherapy, based on histology, primary site, sites of metastasis and level of STM. The limitation of the present subanalysis study was that the IGCCC risk criteria were not applied to many cases because of an unsatisfactory uniform measurement of HCG, as previously described, 6 resulting in difficulties in comparing the results with other reports. However, with the results from analyzed cases that could be categorized by IGCCC classification, it is possible that the IGCCC risk criteria were also a good candidate to predict OS. Therefore, uniform measurement of HCG is highly encouraged.
Another limitation of the present study was that the data were collected from patients with testicular cancer diagnosed in 2005 and 2008, and 10 years have passed since the study. Therefore, it is possible that data analyzed in the present study do not reflect the most current situation regarding chemotherapy for metastatic testicular cancer in Japan. Furthermore, some data, including the RR and STM normalization rate, were not documented in the database. Therefore, we should take those limitations into consideration when analyzing the present study.
The current subanalysis study interestingly suggested that in the multivariate analysis JUA classification and the presence of choriocarcinoma histology at the primary lesion were independent prognostic factors that were associated with OS before starting chemotherapy. These indicate that an initial accurate diagnosis and risk stratification are the key to correlating with better outcomes. Furthermore, STM normalization after completion of the initial series of chemotherapies was the only independent prognostic factor that was associated with OS. The importance of continuous sequential chemotherapy aiming for STM normalization is reconfirmed, as a recent study reported. 14 In conclusion, the initial accurate risk stratification is an important prognostic factor to achieve better oncological outcomes for metastatic testicular cancer patients to undergo chemotherapy. Aiming for STM normalization with continuous sequential chemotherapy could improve OS in patients with NSGCT.
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